Intra-Cellular Therapies Inc’s recent filing unveils that its Director ALEXANDRIA VENTURE INVESTMENTS acquired Company’s shares for reported $1.83 million on Sep 06 ’24. In the deal valued at $73.17 per share,25,000 shares were bought.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Mates Sharon sold 35,604 shares, generating $2,583,884 in total proceeds. Upon selling the shares at $72.57, the Chairman and CEO now owns 1,070,329 shares.
Before that, Mates Sharon sold 34,396 shares. Intra-Cellular Therapies Inc shares valued at $2,505,351 were divested by the Chairman and CEO at a price of $72.84 per share. As a result of the transaction, Mates Sharon now holds 1,070,329 shares, worth roughly $76.2 million.
Piper Sandler upgraded its Intra-Cellular Therapies Inc [ITCI] rating to an Overweight from a a Neutral in a research note published on September 06, 2024; the price target was increased to $92 from $68. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early January with a ‘”an Outperform”‘ rating. TD Cowen began covering ITCI with “an Outperform” recommendation on December 11, 2023. Morgan Stanley started covering the stock on April 20, 2023. It rated ITCI as “an Overweight”.
Price Performance Review of ITCI
On Monday, Intra-Cellular Therapies Inc [NASDAQ:ITCI] saw its stock fall -2.33% to $71.19. Over the last five days, the stock has lost -2.71%. Intra-Cellular Therapies Inc shares have fallen nearly -0.60% since the year began. Nevertheless, the stocks have risen 38.69% over the past one year. While a 52-week high of $84.89 was reached on 04/16/24, a 52-week low of $45.50 was recorded on 02/22/24. SMA at 50 days reached $74.81, while 200 days put it at $71.12.
Levels Of Support And Resistance For ITCI Stock
The 24-hour chart illustrates a support level at 70.33, which if violated will result in even more drops to 69.48. On the upside, there is a resistance level at 72.61. A further resistance level may holdings at 74.03. The Relative Strength Index (RSI) on the 14-day chart is 35.73, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.91, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.03%. Stochastics %K at 9.15% indicates the stock is a buying.
How much short interest is there in Intra-Cellular Therapies Inc?
A steep rise in short interest was recorded in Intra-Cellular Therapies Inc stocks on 2024-09-13, growing by 30448.0 shares to a total of 2.57 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 2.54 million shares. There was a rise of 1.18%, which implies that there is a positive sentiment for the stock.
